7 completed. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 1 | Completed 1 |
Follow Liver Disease: new trials by email Literature Review of Liver Disease trials Research Report on Liver Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016) Efinopegdutide - Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | Merck Sharp & Dohme LLC | 124 | 2024-07-29 | 2026-06-01 |
| Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 26 | 2018-08-01 | 2021-12-14 |
| Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option Alisporivir, Ribavirin - Hepatitis C, Liver Disease | Phase 2 | Completed | Debiopharm International SA | 52 | 2014-03-01 | 2016-10-13 |
| A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency Autologous Expanded CD34+ Haemopoietic cells - Liver Disease | Phase 1 / Phase 2 | Completed | Imperial College London | 5 | 2006-01-01 | 2019-10-31 |
| Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients Alemtuzumab, Cyclosporine, Mycophenolate mofetil - Liver Disease, Liver Transplantation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2005-06-01 | 2012-12-27 |
| Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) Peginterferon alfa-2a, Ribavirin - HIV Infections, Hepatitis C | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 333 | 2004-07-01 | 2021-11-08 |
| A Phase II Study of DMP 115 to Assess Focal Liver Lesions Peflutren Lipid Microsphere Injectable Suspension - Liver Disease | Phase 2 | Completed | Lantheus Medical Imaging | 80 | 2004-03-01 | 2011-08-18 |
Liver Diseases (7) · Hepatitis C (2) · Fibrosis (1) · HIV Infections (1) · Hepatitis D (1) · Non-alcoholic Fatty Liver Disease (1) · Rejection, Psychology (1)
Digestive System Diseases (7) · Hepatitis (3) · Hepatitis, Viral, Human (3) · Infections (3) · RNA Virus Infections (3) · Virus Diseases (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Flaviviridae Infections (2) · Behavior (1) · Fatty Liver (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Lentivirus Infections (1)
Ribavirin (2) · Alemtuzumab (1) · Cyclosporine (1) · Liver Transplantation (1) · Mycophenolic Acid (1) · Ritonavir (1) · Tacrolimus (1) · alisporivir (1) · lonafarnib (1) · peginterferon alfa-2a (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Debiopharm International SA (1) · Imperial College London (1) · Lantheus Medical Imaging (1) · Merck Sharp & Dohme LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
United States (5) · Puerto Rico (2) · United Kingdom (2) · Canada (1) · France (1)
Christopher Koh, M.D. (1) · Edward L.S. Leen, MD (1) · J. Richard Thistlethwaite, MD (1) · Kenneth E. Sherman, MD, PhD (1) · Nagy Habib, ChM FRCS (1) · Raymond Chung, MD (1)
PMID 19268724, PMID 20921898, PMID 21535051, PMID 22510354, PMID 22563020, PMID 23739141